In focus · trending topic

AAV

13 stories · following the connections

Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA

By Nasdaq OMXApr 23, 2018, 12:15 PM UTC

Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

By Nasdaq OMXApr 20, 2018, 12:15 PM UTC

Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer

By Nasdaq OMXApr 2, 2018, 12:15 PM UTC

Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights

By Nasdaq OMXMar 16, 2018, 9:10 PM UTC

Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease

By Nasdaq OMXFeb 12, 2018, 1:45 PM UTC

Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA

By Nasdaq OMXFeb 8, 2018, 7:00 PM UTC

Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial

By Nasdaq OMXFeb 7, 2018, 1:45 PM UTC

Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB

By Nasdaq OMXDec 20, 2017, 1:45 PM UTC